| Predictors of success with highly active antiretroviral therapy in an antiretroviral-naive urban population. | |
| | |
MedLine Citation:
|
PMID: 20156096 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Abstract Predictors of successful virologic, immunologic, and clinical response with combined antiretroviral therapy (cART) containing a boosted protease inhibitor or a nonnucleoside reverse transcriptase inhibitor were analyzed among an antiretroviral naive (ARV-naive) urban cohort. Measures of success included virologic suppression [HIV-1 viral load (VL) <400 copies/ml], an increase in CD4(+) T cells from baseline of >100 cells/microl, and lack of development of an AIDS-defining illness at 24 and 48 weeks after cART initiation. Two hundred and eighty-seven ARV-naive patients were included in this cohort, of which 76.7% were male and 86.8% were nonwhite. At the time of cART initiation their median age was 39 years, the geometric mean CD4(+) count was 42 cells/microl, and the mean viral load was 5.3 log(10) copies/ml. At 48 weeks, 72% of patients achieved virologic suppression, with > or =90% adherence and high school graduation predicting viral undetectability at 48 weeks. Baseline VL < or =100,000 copies/ml and a CD4(+) cell count >100 cells/microl were associated with viral suppression at 24 weeks [OR (95% CI) = 3.55 (1.29-9.81) and 3.96 (1.19-13.15), respectively]; female gender was associated with a greater increase in CD4(+) cell counts [OR (95% CI) = 7.41 (2.48-22.1)]. CDC stage A1-C2 at baseline predicted lack of clinical progression at 48 weeks. The results of this analysis of an ARV-naive cohort comprised predominantly of indigent, minority patients suggest that men who did not have a high school education and who had advanced HIV infection are less likely to have therapeutic success after cART initiation. |
| | |
Authors:
|
Elisa Zaragoza-Macias; Dominique Cosco; Minh Ly Nguyen; Carlos Del Rio; Jeffrey Lennox |
Related Documents
:
|
12032876 - Randomized, open-label, comparative trial to evaluate the efficacy and safety of three ... 11039136 - Effectiveness of antiretroviral therapy initiated before the age of 2 months in infants... 14640386 - Modest decreases in nnrti susceptibility do not influence virological outcome in patien... 20184766 - Regional differences in rates of hiv-1 viral load monitoring in canada: insights and im... 9744676 - Exploring the combined action of lifetime alcohol intake and chronic hepatotropic virus... 21961516 - More than just talk: the framing of transactional sex and its implications for vulnerab... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural |
Journal Detail:
|
Title: AIDS research and human retroviruses Volume: 26 ISSN: 1931-8405 ISO Abbreviation: AIDS Res. Hum. Retroviruses Publication Date: 2010 Feb |
Date Detail:
|
Created Date: 2010-02-16 Completed Date: 2010-04-21 Revised Date: 2011-07-22 |
Medline Journal Info:
|
Nlm Unique ID: 8709376 Medline TA: AIDS Res Hum Retroviruses Country: United States |
Other Details:
|
Languages: eng Pagination: 133-8 Citation Subset: IM; X |
Affiliation:
|
Department of Medicine, Emory University School of Medicine , Atlanta, GA 30303, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Anti-HIV Agents / therapeutic use* Antiretroviral Therapy, Highly Active / methods* CD4 Lymphocyte Count Female HIV Infections / drug therapy*, immunology, virology HIV-1 / isolation & purification Humans Male Middle Aged Prognosis Treatment Outcome Urban Population Viral Load |
| Grant Support | |
ID/Acronym/Agency:
|
2P30 AI 50409-04A1/AI/NIAID NIH HHS; D43 TW01042/TW/FIC NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Anti-HIV Agents |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Evaluation of HIV Type 1 Strains in Men Having Sex with Men and in Female Sex Workers in Mombasa, Ke...
Next Document: Effectiveness of Boosted Protease Inhibitor-Based Regimens in HIV Type 1-Infected Patients Who Exper...